Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

18.26 +0.20 (+1.11%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
31 32 Next >
How Avidity Biosciences Just Dropped The Hammer On Sarepta Therapeutics
The company is coming up fast with a platform that could take on several of Sarepta's approved treatments. 
Via Investor's Business Daily
Smart Money Is Betting Big In SRPT Options
 
Via Benzinga
McKesson Reports Weak Sales, Joins JFrog, Fastly, Warner Bros. Discovery And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
 
Via Benzinga
7 Biotech Stocks to Buy for Their Game-Changing Potential
Although the market may be reeling from the recent fallout, the red ink presents a viable opportunity in these biotech stocks. 
Via InvestorPlace
Sarepta Therapeutics (SRPT) Q2 2024 Earnings Call Transcript
SRPT earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
NASDAQ:SRPT may be ready to breakout.
NASDAQ:SRPT may be ready to breakout. 
Via Chartmill
26 Analysts Have This To Say About Sarepta Therapeutics
 
Via Benzinga
Here's How Much $1000 Invested In Sarepta Therapeutics 10 Years Ago Would Be Worth Today
 
Via Benzinga
Here's How Much $100 Invested In Sarepta Therapeutics 10 Years Ago Would Be Worth Today
 
Via Benzinga
SRPT Stock Earnings: Sarepta Therapeutics Beats EPS, Misses Revenue for Q2 2024
SRPT stock results show that Sarepta Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Sarepta Therapeutics Announces Second Quarter 2024 Financial Results and Recent Corporate Developments
From Sarepta Therapeutics, Inc.
Via Business Wire
3 Genomics Stocks That May Transform Personalized Medicine
These are three of the best genomics stocks to buy for a lucrative entry into a specialized section of the biotech industry. 
Via InvestorPlace
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Expert Outlook: Sarepta Therapeutics Through The Eyes Of 25 Analysts
 
Via Benzinga
Looking At Sarepta Therapeutics's Recent Unusual Options Activity
 
Via Benzinga
Here's How Much You Would Have Made Owning Sarepta Therapeutics Stock In The Last 10 Years
 
Via Benzinga
Sarepta Therapeutics to Announce Second Quarter 2024 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire
SAVA Stock Plunges as Cassava Sciences CEO Steps Down. What to Know.
The CEO of Cassava Sciences is stepping down, effective immediately. Here's what this means for troubled SAVA stock. 
Via InvestorPlace
Jim Cramer Says Don't Sell Match Group: 'You've Just Got A Very, Very Smart Investor In There'
Jim Cramer doesn't favor Fortinet, but owns Palo Alto Networks for charity. Air Products not doing well due to better run company Linde. 
Via Benzinga
Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives
From Cassava Sciences, Inc.
Via GlobeNewswire
After a Big Win, Is Sarepta Therapeutics Stock a Buy?
One key issue remains unresolved, and it could be a significant one. 
Via The Motley Fool
Has Sarepta Therapeutics Become a No-Brainer Stock Buy After This Recent FDA News?
The label expansion paves the way for much more revenue growth for Sarepta in the years ahead. 
Via The Motley Fool
1 Soaring Growth Stock to Buy and Hold for 10 Years
Let's look beyond the biotech's performance this year. 
Via The Motley Fool
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Is Pfizer's Pain Sarepta Therapeutics' Gain? Don't Bet on It.
One company's negative results can increase scrutiny of another's work. 
Via The Motley Fool
Sarepta Therapeutics Scores 90-Plus RS Rating On Muscular Dystrophy Approval
Sarepta Therapeutics had its Relative Strength (RS) Rating upgraded to 95 Monday, up from 68 a day earlier. 
Via Investor's Business Daily
Micron To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Monday
 
Via Benzinga
DraftKings And Dell Were Among The 10 Biggest Large Cap Stock Gainers Last Week (June 16-June 22): Are These In Your Portfolio?
Top performers last week were SRPT (+29.50%), SIRI (+16.73%), TOST (+15.57%), GILD (+12.62%), CHWY (+10.59%), ACN (+9.80%), DKNG (+9.69%), DELL (+8.19%), ADSK (+7.99%), and GFI (+7.15%). 
Via Benzinga
Google Parent Alphabet At All-Time High, In Stock Spotlight: See New Names On IBD 50, Stock Spotlight And More
Alphabet stock has more than doubled since February 2023 and it continues to outperform. It boasts a best-possible 99 Composite Rating. 
Via Investor's Business Daily
Growth Stocks Leave Value Stocks In The Dust: 4 Reasons For Biggest Monthly Lead In Over A Year
Technology sector dominates growth stocks, boosted by strong earnings and investor confidence. Value stocks struggle due to less impressive performance and subdued earnings expectations. Growth... 
Via Benzinga
< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
31 32 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.